Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, single dose, open-label, multicenter crossover study to determine the
oral bioavailability of a new ABT-263 formulation relative to that of the current ABT-263
formulation being administered in ongoing Phase 1/2a studies. Approximately 48 evaluable
subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors
will be enrolled in this study.